Full notification file
General informationNotification NumberB/NL/08/004Member State to which the notification was sentNetherlandsDate of acknowledgement from the Member State Competent Authority05/05/2009Title of the ProjectA Phase 2a Randomized, Placebo-Controlled, Double-Blind, Multicenter Dose Escalation Study, to Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of AG011, in Subjects with Moderately Active Ulcerative ColitisProposed period of release:15/07/2009 to 01/07/2011Name of the Institute(s) or Company(ies)Leiden University Medical Center, Albinusdreef 2
2333 ZA Leiden
PO Box 9600
2300 RC Leiden
The Netherlands;
3. Is the same GMO release planned elsewhere in the Community?NoHas the same GMPt been notified elsewhere by the same notifier?NoGMO characterizationGMO is a:BacteriumIdentity of the GMO:Lactococcus lactis subsp. cremorisInformation relating to the recipient or parental organisms from wich the GMO is derived| Common Name | Genus | Species | Subspecies | Strain | Pathovar | | Lactococcus lactis | Lactococcus | L. lactis | cremoris | MG1363 | |
|
European Commission administrative informationConsent given by the Member State Competent Authority:Not known